Clinical Trials Browser

Borderline Resectable Pancreatic Cancer × Oxaliplatin × Gastrointestinal × Clear all

NCT06387810 2024-07-10

undetermined

Phase 2 Recruiting

Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Phase 2 Unknown

Gastrointestinal

Borderline Resectable Pancreatic Cancer